Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Launched by HERLEV AND GENTOFTE HOSPITAL · Dec 21, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking for new ways to identify and predict the outcomes of treatments for patients with biliary tract cancer, which includes cholangiocarcinoma and gallbladder cancer. Right now, doctors don’t have reliable tests, called biomarkers, to find these cancers early or to see how well a treatment might work. The goal of this study is to discover these important markers so that patients can receive better and earlier care.
If you or someone you know has been diagnosed with biliary tract cancer and is being referred for treatment, you might be eligible to participate in this trial. Participants will need to give their consent to take part in the study. There are no specific exclusions, meaning most patients can join. While in the trial, participants can expect to help researchers learn more about their condition, which could lead to better treatments in the future. This study is currently recruiting participants of all ages from 65 and older.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histological or cytological diagnosis of BTC
- • Patients referred for treatment of BTC
- • Signed informed consent
- Exclusion Criteria:
- • None
About Herlev And Gentofte Hospital
Herlev and Gentofte Hospital, a leading healthcare institution in Denmark, is dedicated to advancing medical research and patient care through innovative clinical trials. As a prominent sponsor, the hospital focuses on a wide range of therapeutic areas, leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate rigorous scientific investigation. Committed to enhancing treatment outcomes and improving patient quality of life, Herlev and Gentofte Hospital collaborates with academic institutions and industry partners to foster groundbreaking discoveries and translate research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Herlev, Copenhagen, Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials